secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016847
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q3 net loss widens to $86.7M on 45% revenue decline; CIMERLI projected >$100M in 2023
--------------------------------------------------------------------------------

- Q3 2022 net revenue $45.4M (down from $82.5M YoY); net loss $86.7M ($1.11 loss per share).
- GAAP EPS loss $1.11 vs $0.49 loss YoY; non-GAAP EPS loss $0.96 vs $0.34 loss.
- CIMERLI launched Oct 3, 2022; 2023 net sales projected >$100M; leading biosimilar market share.
- Toripalimab BLA target action date Dec 23, 2022; FDA inspections hindered by COVID travel restrictions.
- Targeting profitability in 2024; planning 2023 launches of YUSIMRY, toripalimab, UDENYCA OBI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/0001558370-22-016847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/chrs-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer